Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-07-01 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2020年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance qualifications, agenda, and voting results of the 2020 second extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It details the legal compliance of the meeting's call, conduct, and voting results, including the approval of specific resolutions. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process and outcomes. This type of document corresponds to the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting and confirms their legality and validity.
2020-07-01 Chinese
2020年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2020 second extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, attendance, voting results on multiple proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and procedural details of the shareholders' meeting. There is no financial data, earnings information, or management discussion. The document is not a report itself but an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and contains detailed voting results, consistent with DVA filings rather than a report publication announcement or regulatory filing.
2020-07-01 Chinese
关于股东减持股份计划实施完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholder's share reduction plan. It details the number of shares reduced, the method of reduction, the period, and the shareholding before and after the reduction. It references compliance with relevant regulations on shareholder and insider share reductions. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a director's share transaction (shareholder reducing holdings). This fits the category of Director's Dealing (DIRS). The document length is short and focused solely on the share reduction completion, not a report or announcement of a report publication.
2020-07-01 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of a significant shareholder (浙江贝成投资管理合伙企业) in 贝达药业股份有限公司, including the number of shares held before and after the change, the method of share reduction, and related disclosures. The document references compliance with Chinese securities laws and disclosure requirements for equity changes. It does not contain financial statements or earnings data, nor is it an announcement of a meeting or voting results. It is a formal notification of a change in major shareholding levels, specifically indicating the shareholder's holdings dropped below 5%. This fits the definition of a Major Shareholding Notification (MRQ). The document length and detail confirm it is the report itself, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2020-06-29 Chinese
关于股东减持公司股份后持股比例低于5%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a shareholder reducing their stake in the company below the 5% threshold. It details the number of shares held before and after the reduction, the method and price of the share sales, and confirms compliance with relevant regulations. It also references related filings such as a simplified equity change report. This type of document is a Major Shareholding Notification, as it informs the market and regulators about changes in significant share ownership levels crossing thresholds (in this case, falling below 5%). The document is not an annual report, earnings release, or any other financial report, nor is it a general regulatory filing or announcement of a report. Therefore, the correct classification is Major Shareholding Notification (MRQ). The confidence in this classification is very high given the clear content and context.
2020-06-29 Chinese
独立董事关于第三届董事会第八次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion related to the company's third board meeting's eighth session. It references compliance with Chinese securities regulations and discusses a shareholder proposal and board meeting agenda regarding an investment project. The document is short (1124 characters) and consists mainly of an opinion statement rather than detailed financial data or full report content. It does not contain financial statements or comprehensive financial analysis. It is not an announcement of voting results, nor a full annual or interim report. It is a regulatory compliance-related document expressing independent directors' opinions on board matters, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a formal regulatory disclosure.
2020-06-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.